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ABSTRACT
Background: Maternal cannabis use in pregnancy is linked with long-term adverse behavioral
outcomes in offspring. Epigenetic processes established in utero that affect dopaminergic (reward)
signaling may mediate risks. Associations between cannabis use and offspring DNA methylation
have not been investigated; however, maternal tobacco smoking in pregnancy is associated with
distinct patterns of DNA methylation at birth and beyond. Objectives: To determine whether
maternal cannabis use is associated with methylation of the dopamine receptor gene DRD4
promoter in infants. Methods: Mothers in the Triple B study provided detailed information on
drug use in each trimester of pregnancy. Buccal swabs were collected from neonates at 8 weeks (n
= 804, 51.7% male, and 48.3% female). DRD4 promoter DNA methylation was measured using
SEQUENOM MassARRAY. Results: Fifty-seven of the women in the study reported drug use during
pregnancy, of whom 44 used cannabis. Of 19 cytosine-phosphate-guanine dinucleotides (CpG)
units tested in DRD4, gestational cannabis use was associated with offspring methylation at 1 CpG
unit in multivariate models (β + 1.48, CI: 0.02 to 2.93, and p = 0.047). At another site there was
weak evidence that both cannabis and other drug use were independently associated with
increased methylation, while the association with tobacco was in the reverse direction (cannabis
use β + 0.67, CI: −0.12 to 1.46, and p = 0.09; other drug use β + 1.11, CI: 0.17 to 2.05, and p = 0.02;
tobacco use β −0.41, CI: −0.85 to 0.03, and p = 0.07). None of the associations would remain
significant after correction for multiple testing. Conclusion: There is no strong evidence that
maternal cannabis use in pregnancy is associated with offspring DRD4 methylation.
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Introduction
Drug or “substance” use during pregnancy is relatively
common, reported by up to 5% of women in the gen-
eral population, with cannabis the most frequently used
(1). Given the changing prevalence of use related to
legislative changes in some countries (i.e., increasing
use with decriminalization), studies concerning mater-
nal cannabis use are an important consideration for
public health (2,3).
Although research into the effects of prenatal expo-
sure to maternal cannabis use on offspring is still in its
infancy, adverse effects have been reported. A recent
meta-analysis involving 24 studies found that cannabis-
exposed infants had a higher risk of anemia, decreased
birth weight, and a greater chance of being placed in
intensive care (4). Subsequent studies have reported
similar findings (5) as well as longer-term detrimental
effects. Mothers who used cannabis daily in the first
trimester had offspring with deficits in verbal reasoning
and short-term memory in childhood (6) and any in
utero exposure has been associated with attention pro-
blems and increased aggression in 18-month-old girls
(7). Heavy cannabis use (one or more joints a day)
during the first trimester of pregnancy has also been
associated with lower reading, spelling, maths, and
comprehension skills in 10-year-old primary school
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students (8), which may be due in part to an increased
risk of mood disorders such as anxiety and depression.
The detrimental effects of cannabis could result from
the transmission of Δ9-tetrahydrocannabinol (THC),
the psychoactive constituent within cannabis, to the
fetus (9). THC can readily cross the placenta, it has
been shown to increase the diameter of umbilical veins
and arteries, and THC stimulation of endocannabinoid
signaling may induce apoptosis of developing placental
cytotrophoblasts (10). Thus biologically available THC
can have a negative impact on the fetus in utero. Given
its key role in prenatal development and association
with several postnatal phenotypes in humans, epige-
netic mechanisms may help mediate these short-term
and long-term detrimental effects (11). Broadly, epige-
netics refers to environmentally sensitive alterations in
gene expression that do not change the underlying
DNA sequence (12). DNA methylation, particularly
methylation of cytosine-phosphate-guanine dinucleo-
tides (CpG), is the most commonly studied epigenetic
mechanism.
Most epigenetic studies of cannabis have focused on
the effects of cannabis use in adults, primarily investi-
gating the THC cannabinoid receptor type 1 (CNR1)
which encodes the receptor CB1R. Elevated methylation
of the CNR1 promoter and downregulation of CB1R
mRNA, as measured in peripheral blood, is associated
with cannabis use in schizophrenia patients (13).
Methylation levels were also related to the severity
and frequency of cannabis cravings. CB1R is known to
be co-expressed with dopamine receptors (14) and
cannabis, like all recreational drugs, causes an increase
in dopamine levels in the terminal regions of the meso-
limbic dopamine system. Dopamine signaling is linked
to memory, cognition, and is one of the major reward
pathways in the brain implicated in drug addiction
(15). Little is known about the effects of maternal
cannabis use on methylation of genes involved in dopa-
mine signaling in offspring.
The primary aim of this study was to determine the
association between maternal gestational cannabis use
and offspring DNA methylation. Of the set of genes
controlling neuro-signaling within dopaminergic path-
ways, this study focused on offspring DRD4 methyla-
tion patterns given that this gene has not only been
associated with substance use (16) and addiction
(17,18), but importantly has also been linked to infant
health outcomes, including birth weight, behavior, and
neurodevelopment (19,20). Differential methylation of
this gene could thus help mediate the association
between maternal substance use and poor infant health
outcomes, although no studies to date have yet mea-
sured DRD4 methylation in this regard.
The secondary aim was to investigate how maternal
tobacco smoking could influence the association
between cannabis and infant methylation. Most studies
to date do not differentiate cannabis from tobacco use,
despite the fact that cannabis is often smoked together
with tobacco, and tobacco has similar effects on infant
health. This is problematic because maternal smoking
during pregnancy has been consistently shown to influ-
ence infant DNA methylation in peripheral tissue and
to mediate the association between prenatal exposure
(21,22) and infant birth weight (23). Furthermore, a
very recent study found that cannabis alone had no
independent effect on perinatal outcomes, but augmen-
ted the risk associated with tobacco smoking (24).
Studies examining effects associated with tobacco and
cannabis in isolation and in combination are needed to
elucidate unique effects.
Methods
Triple B pregnancy cohort
This longitudinal pregnancy cohort of 1,634 families is
focused on perinatal maternal lifestyle factors and
infant health outcomes. Families were recruited
through general public and specialist drug and alcohol
antenatal services at major hospitals in New South
Wales and Western Australia (25). Mother–infant
dyads with major medical complications were excluded.
Written informed consent was provided by all partici-
pants, and all relevant human research ethics commit-
tees approved the study. In-depth health, lifestyle, and
sociodemographic data were collected across pregnancy
and postpartum. This included detailed questionnaires
about drug use in each trimester of pregnancy and the
first 8 weeks postpartum.
Methylation analysis
The DRD4 methylation assay covered a 396 base pair
region of the gene promoter spanning chr11:635,510–
636,905 (UCSC hg38), previously shown to be differ-
entially methylated in association with attention deficit
hyperactivity disorder (ADHD) (26). Infant buccal
swabs were collected at 8 weeks of age. Extracted
DNA underwent bisulfite conversion (EZ-96 DNA
Methylation-LightningTM MagPrep kit (Irvine, CA)),
followed by PCR amplification in triplicate with pri-
mers 5ʹ-GGACCCCCTGCCCAGGGTCAGAGG-3ʹ and
5ʹ-TGCCAGATACCAGGTGGACTAGGGTG-3ʹ, and
Sequenom MassARRAY analysis (27). Average DRD4
methylation was calculated after excluding any tripli-
cate samples deviating by ≥10% from the median.
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Outlying data (>10% outside 1.5xIQR) were excluded,
as were CpG units (n = 4) and participants with <85%
data retained after quality control (n = 92). Health,
lifestyle, and sociodemographic data did not differ sig-
nificantly between excluded participants and those
included in this analysis.
Statistical analysis
To investigate the association between prenatal mater-
nal substance use (yes/no) with infant DRD4 promoter
methylation, t-tests were used for univariate analysis,
followed by multivariate linear regression models
adjusted for potential confounding factors, and
Sequenom batch effects.
Results
Table 1 shows the maternal and infant characteristics of
the population according to cannabis use during preg-
nancy. Cannabis use was the most commonly used
drug (n = 44, 77.2% of drug users) and was most
common among mothers in trimester 1 (Table 2), likely
prior to knowledge of pregnancy. Of those who
reported cannabis use, eight used cannabis daily
throughout trimester 1, with the dose ranging between
(the equivalent of) 0.5 and 7 joints. A total of 29
women used other types of drugs, with the type and
quantity varying quite considerably. Of these women,
16 also used cannabis.
We first investigated the association between any
type of substance use during pregnancy and infant
DRD4 promoter methylation. Of 19 CpG units tested,
the only evidence of an association was a very small
increase in methylation at CpG.32 (Δ + 0.78, 95% CI:
0.17–1.38%, and p = 0.012) (Figure 1, Table S1).
Cannabis use was similarly associated with differential
methylation at the same site (Δ + 0.79, 95% CI: 0.11–
1.46%, and p = 0.023) (Figure 2, Table S2). These
associations remained even after adjustment for covari-
ates, including drug use at 8 weeks postpartum, given
the potential for effects resulting from exposure during
breastfeeding or second-hand exposure. Smoking
tobacco during pregnancy was itself associated with
DRD4 methylation at this same site, but in the reverse
direction (cannabis: β + 0.77, 95% CI: 0.06 to 1.48, and
p = 0.032; tobacco: β −0.41, 95% CI: −0.85 to 0.03, and
p = 0.072). However, when adjusting for other sub-
stance use as a covariate, which was also associated
with increased CpG.32 methylation, the association
with cannabis becomes nonsignificant (cannabis: β +
0.67, 95% CI: −0.12 to 1.46, and p = 0.098; other
substance use: β + 1.11, 95% CI: 0.17 to 2.05, and p =
0.020). Cannabis use was also associated with increased
methylation at CpG.21.22.23 when we adjusted for
tobacco use in the multivariate model (β + 1.48, 95%
CI: 0.02 to 2.93, and p = 0.047, unadjusted Δ + 1.03,
95% CI: −0.29% to 2.36%, and p = 0.13), and regardless
of other drug use. Out of interest, adding alcohol use
during pregnancy to these models did not alter the
associations seen.
Table 1. Maternal and infant population characteristics accord-
ing to maternal cannabis use during pregnancy (N = 804*).
Characteristic Cannabis use during pregnancy
No (n = 760) Yes (n = 44)
Maternal Mean ± SD
Age at child’s birth (years) 32.6 ± 4.8 30.2 ± 6.5
Country of birth: N (%)
Australia 418 (55.0) 36 (81.8)
Other 342 (45.0) 8 (18.2)
Currently living with partner 720 (94.7) 29 (65.9)
Education level:
Year 12 or under 124 (16.3) 25 (56.8)
Completed TAFEa/tech schoolb 104 (13.7) 9 (20.5)
Completed university/college 532 (70.0) 10 (22.7)
Employment:
Full time/self-employed 362 (47.6) 11 (25.0)
Part time/casual 145 (19.1) 5 (11.4)
Home/student/unemployed 253 (33.3) 28 (63.6)
Substance use during pregnancy:
Tobacco use 100 (13.2) 35 (79.6)
Alcohol consumption 514 (67.6) 35 (79.6)
Infant
Sex:
Male 389 (51.3) 26 (59.1)
Female 370 (48.7) 18 (40.9)
Mean ± SD
Gestational age (weeks) 39.4 ± 1.6 39.0 ± 2.0
Birth weight (kg) 3.5 ± 0.5 3.3 ± 0.7
aTAFE: Technical and further education institutions.
bTechnical school: Similar to TAFE but more trade oriented.
*Except for infant sex and gestational age (n = 803), and birth weight (n = 801).
Table 2. Maternal substance use across pregnancy and at 8 weeks postpartum.
N (%)
Drug Trimester 1 Trimester 2 Trimester 3 Any time during pregnancy 8 weeks postpartum
Cannabis 44 (5.5) 19 (2.4) 11 (1.4) 44 (5.6) 15 (1.9)
Heroin 8 (1.0) 3 (0.4) 2 (0.3) 8 (1.0) 0 (0)
Non-prescribed opioids 1 (0.1) 1 (0.1) 0 (0) 1 (0.1) 1 (0.1)
Amphetamines 11 (1.4) 1 (0.1) 0 (0) 13 (1.5) 1 (0.1)
Cocaine 10 (1.2) 0 (0) 0 (0) 11 (1.2) 1 (0.1)
Hallucinogens 3 (0.4) 1 (0.1) 0 (0) 3 (0.4) 0 (0)
Club drugs 5 (0.6) 0 (0) 0 (0) 5 (0.6) 0 (0)
Total 56 (7.0) 20 (2.5) 9 (1.1) 57 (7.1) 16 (1.9)
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Figure 1. Methylation of infant DRD4 CpG.32 according to maternal substance use during pregnancy.
Figure 2. Mean infant DRD4 promoter methylation according to maternal cannabis use during pregnancy. Bars indicate 95% CI.
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Given that cannabis is frequently taken together
with tobacco, we further compared DRD4 promoter
methylation levels across four groups: no drug or
tobacco use (n = 658), tobacco alone (n = 96), can-
nabis alone (n = 9), and both cannabis and tobacco
(n = 35). Only cannabis use appeared to increase
methylation compared to no substance use
(Table 3). In addition, exclusive cannabis use was
associated with 2.08% higher methylation at CpG.32
compared to tobacco use alone (95% CI: 0.19–3.96%
and p = 0.024). Exclusive cannabis use compared to
combined cannabis and tobacco showed no signifi-
cant difference in DNA methylation (p = 0.48).
Discussion
Here we report a nominally significant association
between cannabis use during pregnancy and
increased DRD4 promoter methylation at one CpG
site (CpG11:636796, hg38) in infants, which
remained after adjustment for concurrent tobacco
use. We also found some, although nonsignificant,
evidence that both other drug use and cannabis use
appeared to increase methylation at another site,
while tobacco smoking had a reverse effect
(decreased methylation). This is despite reports that
cannabis and tobacco have similar (28) and even
cumulative detrimental effects on infant health (24).
However, the overall effect sizes observed are very
small and the strength of association would not
remain if corrected for multiple testing (using a
Bonferroni corrected significance level of 0.0026
given the 19 CpG units examined).
Dopamine signaling is involved in many cognitive
processes, including memory and reward (15).
Cannabis dependence is linked to a reduction in
striatal dopamine release which is also correlated
with poor working memory and learning perfor-
mance (29). Prenatal cannabis exposure has been
associated with decreased dopamine receptor D2
expression in human fetal brain specimens (30).
Dopamine receptor deficiency has been linked to
increased choice and immediacy to use drugs, and
is observed in people with substance use disorders
(31). DRD4, a D2-like dopamine receptor, was cho-
sen as a strong candidate gene in this study due to its
key role in dopamine signaling, and its links to drug
use in genetic association studies. A DRD4 variable
number tandem repeat has been associated with
increased problematic cannabis use (32), and a heigh-
tened risk of externalizing behavior problems that
contribute to substance use disorders and addiction
(33). DRD4 genetic variants can also moderate the
effect of prenatal stress on children’s antisocial beha-
vior (34). Furthermore, increased DRD4 methylation
in saliva has been associated with increased severity
of ADHD symptoms in children (35).
Our study is strengthened by the in-depth data
concerning substance use and tobacco smoking
across pregnancy and the large sample size. The
percentage of women using drugs during pregnancy
(7.03%) was higher than that reported in the general
Australian population (2.2%) (36). Our study had
over 80% power (α = 0.05, two-sided) to detect a
minimum effect size of 0.385 standard deviation (SD)
difference in the mean methylation between groups.
For CpG.32 for example, with a group SD of 2.2, our
study could detect a methylation difference of 0.86%
between groups defined by drug use. The power of
the analysis was nevertheless limited, particularly in
regard to the timing or dose of exposure during
pregnancy, which could not be investigated, or spe-
cific drugs other than cannabis, which are likely to
have varying effects on methylation and infant health
outcomes (37). Tissue specificity of DNA methylation
marks may contribute to the largely negative findings
of our study. Dopamine signaling is prominent in the
brain, but due to the limitations in accessing such
tissue, we chose to investigate buccal cell DNA
methylation, given that (1) buccal epithelial cells
have the same developmental origins to neuronal
cells (i.e., derive from ectoderm) and (2) previous
studies have provided some support for the use of
buccal cells as a proxy for neurodevelopmental phe-
notypes (38). The power of the study may have been
limited due to underreporting of maternal substance
use, which could help explain the predominantly
negative findings (if a proportion of women classified
as nonusers had in fact used drugs during preg-
nancy). However, to address this limitation in the
Triple B study, a random selection of 85 participants
provided urine samples for analysis in the third tri-
mester of pregnancy. There was 97% agreement
between self-report substance use and urine analysis,
indicating the overall high accuracy of the self-report
data. Other limitations are that we could not properly
Table 3. Infant DRD4 CpG.32 methylation when comparing
substance use groups to no substance use during pregnancy.
Substance group Difference (%) 95% CI p Value
Smoking only −0.36 −0.99 to 2.65 0.45
Cannabis only 1.71 −0.09 to 3.52 0.069
Both smoking and cannabis 0.59 −0.38 to 1.56 0.40
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investigate the independent effects of tobacco from
cannabis, as only nine cannabis users in the study did
not smoke tobacco.
Conclusion and future research
We found no convincing evidence of an association
between prenatal substance use overall or cannabis use
and differential infant DRD4 methylation. However,
given the reported effects of maternal drug use on infant
health outcomes, as well as consistent evidence that smok-
ing tobacco during pregnancy influences infant peripheral
DNA methylation, it is possible that genes other than
DRD4 may be involved, such as CNR1. Further studies
could investigate other components of dopaminergic sig-
naling, or use a more unbiased discovery approach such
as an epigenome-wide association study. Both approaches
would benefit from a substantially larger sample of mater-
nal drug users. Such approaches are essential to provide a
better understanding of the biological mechanisms
underlying the association between prenatal drug expo-
sure and infant health outcomes.
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